Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
(CB-01-02/01)Randomized Placebo Controlled Trial of Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg in Patients With Ulcerative Colitis
This study has been completed.
Study NCT00679432 Information provided by Santarus
First Received on May 14, 2008. Last Updated on February 9, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Ulcerative Colitis
Additional conditions recognized in this trial
Colitis
Colitis, Ulcerative
Ulcer
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Inflammatory Bowel Diseases
Intestinal Diseases
Pathologic Processes
Interventions listed in this trial
Blood sampling, endoscopy
budesonide-MMX® 6 mg
budesonide-MMX® 9 mg
Placebo
Asacol® 400 mg
Additional drug interventions recognized in this trial
Budesonide
Mesalamine
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Autonomic Agents
Bronchodilator Agents
Central Nervous System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Santarus
Back to top of Main Content
